Drugs / intravenous immunoglobulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02878616 | Aug 2016 → Jul 2017 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | intravenous immunoglobulin | “concomitant treatment with intravenous immunoglobulin (IVIG) can alter the pharmacokinetics and pharmacodynamics of LFG316” NCT02878616 ↗ |
| Known as | IVIg | “concomitant treatment with intravenous immunoglobulin (IVIG) can alter the pharmacokinetics and pharmacodynamics of LFG316” NCT02878616 ↗ |
| Modality | Protein / enzyme biologic | “high-dose intravenous immunoglobulin (IVIg)” PMID 32301258 ↗ May 2020 |
| Route | Intravenous | “intravenous immunoglobulin (IVIg)” NCT02878616 ↗ |